|
|||||
|
|
| 药品开发主体分析 | |
| 引用本文： | 治部真里,李颖.药品开发主体分析[J].情报工程,2015,1(2):008-020. |
| 作者姓名： | 治部真里 李颖 |
| 作者单位： | 日本科学技术振兴机构,中国科学技术信息研究所 |
| 基金项目： | “面向科技文献的日汉双向实用型机器翻译合作研究”(项目编号：2014DFA11350) |
| 摘 要： | 日本版NIH及其制药企业，政策制定·战略规划需要佐证。本研究尝试基于新的指标体系进行制药产业的现状俯瞰与预测未来。连载第三篇着眼于持有在研药物(pipeline)主体的规模及其种类，分析了掌控医药品开发的关键主体。其结果表明美国的强项在于中小企业与创业企业。另一方面，日本中小企业与创业企业没有承担像美国那样的角色。 |
| 关 键 词： | 日本版NIH，药品，在研药物，指标，研究开发，偱证政策，开放创新，中小企业，创业企业 |
Special articles |
|
| Authors: | JIBU Mari and LI Ying |
| Institution: | Japan Science and Technology Agency and Institute of Scientific and Technical Information of China |
| Abstract: | For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried an overview and future prospects of pharmaceutical industry based on new indicators. Focusing on the sizes and categories of the entities possessing pipelines, we analyzed who the key entity is in terms of drug R&D. Results show that the SMEs and ventures give strong advantage in the drug R&D in U. S. On the other hand, the SMEs and ventures in Japan do not play a vital role like those in U. S. does. |
| Keywords: | Japanese version of the NIH pharmaceuticals pipeline indicator research and development evidence based policy open innovation small and medium enterprise venture |
| 点击此处可从《情报工程》浏览原始摘要信息 | |
| 点击此处可从《情报工程》下载免费的PDF全文 | |